Human amylin stimulates inflammatory cytokine secretion from human glioma cells

NeuroImmunoModulation

Volumn 7, Issue 3, 2000, Pages 147-152

  Gitter, Bruce D ^a   Cox, Laura M ^a   Carlson, Christopher D ^a   May, Patrick C ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Alzheimer's disease; Amylin; Neuroinflammation

Indexed keywords

AMYLIN;

AGING; ALZHEIMER DISEASE; ARTICLE; ASTROCYTOMA; CELL STIMULATION; CONCENTRATION RESPONSE; CYTOKINE RELEASE; EXTRACELLULAR CALCIUM; GLIOMA CELL; HUMAN; HUMAN CELL; INFLAMMATORY CELL; MEDIATOR RELEASE; NERVE DEGENERATION; PRIORITY JOURNAL; SEQUENCE HOMOLOGY; SUPERNATANT;

EID: 0034079203     PISSN: 10217401     EISSN: None     Source Type: Journal    
DOI: 10.1159/000026432     Document Type: Article

References (49)

1. Hardy J, Allsop D: Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 1991;12:383-388.
2. Glenner GG, Wong CW: Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984; 120:885-890.
3. Selkoe DJ: Cell biology of the amyloid beta-protein precursor and the mechanism of Alzheimer's disease. Annu Rev Cell Biol 1994;10: 373-403.
4. Schenk D, Rydel RE, May P, Little S, Panetta J, Lieberburg I, Sinha S: Therapeutic approaches related to amyloid-β peptide and Alzheimer's disease. J Med Chem 1995;38:4141-4154.
5. Selkoe DJ: Alzheimer's disease: Genotypes, phenotype and treatments. Science 1997;275: 630-631.
6. McGeer PL, Rogers J, McGeer EG: Neuroimmune mechanisms in Alzheimer's disease pathogenesis. Alzheimer Dis Assoc Disord 1994;8:149-158.
7. Vandenabeele P, Fiers W: Is amyloidosis during Alzheimer's disease due to an IL-1/IL-6-mediated 'acute phase response' in the brain? Immunol Today 1991;12:217-219.
8. Aisen PS, Davis KL: Inflammatory mechanisms in Alzheimer's disease: Implications for therapy. Am J Psychiatry 1994;151:1105-1113.
9. Griffin WST, Stanley LC, Ling C, White L, MacLeod V, Perrot LJ, White CL III, Araoz C: Brain interleukin-1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer's disease. Proc Natl Acad Sci USA 1989;86:7611-7615.
10. Ishizuka K, Kimura T, Igata-yi R, Katsuragi S, Takamatsu J, Miyakawa T: Identification of monocyte chemoattractant protein-1 in senile plaques and reactive microglia of Alzheimer's disease. Psychiatry Clin Neurosci 1997;51: 135-138.
11. Griffin WST, Sheng JG, Roberts GW, Mrak RE: Interleukin-1 expression in different plaque types in Alzheimer's disease: Significance in plaque evolution. J Neuropathol Exp Neurol 1995;54:276-281.
12. Griffin WST, Sheng JG, Royston MC, Gentleman SM, McKenzie JE, Graham DI, Roberts GW, Mrak RE: Glial-neuronal interactions in Alzheimer's disease: The potential role of a 'cytokine cycle' in disease progression. Brain Pathol 1998;8:65-72.
13. Busciglio J, Lorenzo A, Yankner BA: Methodological variables in the assessment of beta-amyloid neurotoxicity. Neurobiol Aging 1992; 13:609-612.
14. Pike CJ, Burdick D, Walencewicz AJ, Glabe CG, Cotman CW: Neurodegeneration induced by β-amyloid peptides in vitro: The role of peptide assembly state. J Neurosci 1993;13:1676-1687.
15. Simmons LK, May PC, Tomaselli KJ, Rydel RE, Fuson KS, Brigham EF, Wright S, Lieberburg I, Becker GW, Brems DN, Li WY: Secondary structure of amyloid β peptide correlates with neurotoxic activity in vitro. Mol Pharmacol 1993;45:373-379.
16. Lorenzo A, Yankner BA: β-amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc Natl Acad Sci USA 1994; 91:12243-12247.
17. Pike CJ, Walencewicz-Wasserman AJ, Kosmoski J, Cribbs DH, Glabe CG, Cotman CW: Structure-activity analysis of β-amyloid peptides: Contributions of the β25-35 region to aggregation and neurotoxicity. J Neurochem 1995;64:253-265.
18. Gitter BD, Cox LM, Rydel RE, May PC: Amyloid β potentiates cytokine secretion by interleukin-1β-activated human astrocytoma cells. Proc Natl Acad Sci USA 1995;92:10738-10741.
19. Barger SW, Hoerster D, Furukawa K, Goodman Y, Krieglstein J, Mattson MP: Tumor necrosis factor-α and β protect neurons against amyloid β-peptide toxicity: Evidence for involvement of a κb binding factor and attenuation. Proc Natl Acad Sci USA 1995;92:9328-9332.
20. Mattson MP, Cheng B, Davis D, Bryant K, Lieberburg I, Rydel RE: β-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci 1992;12:376-389.
21. Mattson MP, Barger SW, Cheng B, Lieberburg I, Smith-Swintosky VL, Rydel RE: β-Amyloid precursor protein metabolites, neuronal calcium homeostasis, and the pathogenesis of Alzheimer's disease. Trends Neurosci 1993;16: 409-414.
22. Lorton D: β-Amlyoid-induced IL-1β release from an activated human monocyte cell line is calcium-and G-protein-dependent. Mech Ageing Dev 1997;94:199-211.
23. May PC, Boggs LN, Fuson KS: Neurotoxicity of human amylin in rat primary hippocampal cultures: Similarity to Alzheimer's disease amyloid-β neurotoxicity. J Neurochem 1993; 61:2330-2333.
24. Dore S, Kar S, Quirion R: Insulin-like growth factor I protects and rescues hippocampal neurons against β-amyloid-and human amylin-induced toxicity. Proc Natl Acad Sci USA 1997;94:4772-4777.
25. Tucker HM, Rydel RE, Wright S, Estus S: Human amylin induces 'apoptotic' pattern of gene expression concomitant with cortical neuronal apoptosis. J Neurochem 1998;71:506-516.
26. Lorenzo A, Razzaboni B, Weir GC, Yankner BA: Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. Nature 1994;368:756-760.
27. MacGibbon GA, Cooper GJS, Dragunow M: Acute application of human amylin, unlike β-amyloid peptides, kills undifferentiated PC12 cells by apoptosis. Neuroreport 1997;8:3945-3950.
28. Cooper GJS, Wills AC, Clark A, Turner RC, Sim RB, Reid KBM: Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci USA 1987;84:8628-8632.
29. Westermark P, Wernstedt C, Wilander E, Hayden DW, O'Brien TD, Johnson KH: Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells. Proc Natl Acad Sci USA 1987; 84:3881-3885.
30. McLean LR, Balasubramanium A: Promotion of β-structure by interaction of diabetes-associated polypeptide (amylin) with phosphatidyl choline. Biochem Biophys Res Commun 1992; 1112:317-320.
31. Cort J, Liu Z, Lee G, Harris SM, Prickett KS, Gaeta, Anderson NH: β-Structure in human amylin and two designer β-peptides: CD and NMR spectroscopic comparisons suggest soluble β-oligomers and the absence of significant populations of β-strand dimers. Biochem Biophys Res Commun 1994;204:1088-1095.
32. Asai J, Nakazato M, Kangawa K, Matsukura S, Matsuo H: Isolation and sequence determination of rat islet amyloid polypeptide. Biochem Biophys Res Commun 1989;164:400-405.
33. Westermark P, Engstrom U, Johnson KH, Westermark GT, Bctsholtz C: Islet amyloid polypeptide: Pinpointing amino acid residues linked to amyloid fibril formation. Proc Natl Acad Sci USA 1990;87:5036-5040.
34. Balasubramanium A, Renugopalakrishnan V, Stein M, Fisher JE, Chance WT: Syntheses, structures and anorectic effects of human and rat amylin. Peptides 1991;12:919-924.
35. Araujo DM, Cotman CW: β-Amyloid stimulates glial cells in vitro to produce growth factors that accumulate in senile plaques in Alzheimer's disease. Brain Res 1992;569:141-145.
36. Haga S, Kazuhiko I, Sato M, Tsuyhoshi I: Synthetic Alzheimer amyloid β/A4 peptides enhance production of complement C3 component by cultured microglial cells. Brain Res 1993;601:88-94.
37. Ii M, Sunamoto M, Ohnishi K, Ichimori Y: β-Amyloid protein-dependent nitric oxide production from microglial cells and neurotoxicity. Brain Res 1996;720:93-100.
38. Lorton D, Kocsis J-M, King L, Madden K, Brunden KR: β-Amyloid induces increases release of interleukin-1β from lipopolysaccharide-activated human monocytes. J Neuroimmunol 1996;67:21-29.
39. Klegaris A, Walker DG, McGeer PL: Interaction of Alzheimer β-amyloid peptide with the human monocytic cell line THP-1 results in a protein kinase C-dependent secretion of tumor necrosis factor-α. Brain Res 1997;747:114-121.
40. Johnstone M, Gearing AJH, Miller KM: A central role for astrocytes in the inflammatory response to β-amyloid; chemokines, cytokines and reactive oxygen species are produced. J Neuroimmunol 1999;93:182-193.
41. Gitter BD, Regoli D, Howbert JJ, Glasebrook AL, Waters DC: Interleukin-6 secretion from human astrocytoma cells induced by substance P. J Neuroimmunol 1994;51:101-108.
42. Kasahara T, Mukaida M, Yamashita K, Yagisawa H, Akahoshi T: IL-I and TNF-α induction of IL-8 and monocyte chemotactic and activating factor (MCAF) mRNA expression in a human astrocytoma cell line. Immunology 1991;74:60-67.
43. Hom JT, Estridge T, Pechous P, Hyslop PA: The amyloidogenic peptide human amylin augments the inflammatory activities of eosinophils. J Leukocyte Biol 1995;58:526-532.
44. Mattson MP, Goodman Y: Different amyloidogenic peptides share a similar mechanism of neurotoxicity involving reactive oxygen species and calcium. Brain Res 1995;676:219-224.
45. Estus S, Tucker HM, van Rooyen C, Wright S, Brigham EF, Wogulis M, Rydel RE: Aggregated amyloid-β protein induces cortical neuronal apoptosis and concomitant 'apoptotic' pattern of gene induction. J Neurosci 1997;17: 7736-7745.
46. May PC, Gitter BD, Waters DC, Simmons LK, Becker GW, Small JS, Robinson PM: β-Amyloid peptide in vitro toxicity: Lot-to-lot variability. Neurobiol Aging 1992;13:605-607.
47. May PC: Commentary: Amyloid-β deposits: Can you take them to the bank? Alzheimer's Dis Rev 1997;2:15-19.
48. Ludvik B, Kautzky-Willer A, Prager R, Thomaseth K, Pacini G: Amylin: History and Overview. Diabetic Med 1997;14:S9-S13.
49. Castillo MJ, Schecn AJ, Lefebvre PJ: Amylin/ islet amyloid polypeptide: Biochemistry, physiology, pathophysiology. Diabetes Metab 1995; 21:3-25.